For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240702:nRSB6809Ua&default-theme=true
RNS Number : 6809U hVIVO PLC 02 July 2024
hVIVO plc
("hVIVO", the "Company" or the "Group")
Capital Markets Event and Trading Update on 17 July
hVIVO plc (AIM & Euronext: HVO), a fast growing specialist contract
research organisation (CRO) and world leader in testing infectious and
respiratory disease products using human challenge clinical trials, announces
that it will be holding a Capital Markets Event at the Company's new
state-of-the-art facility in Canary Wharf for analysts, institutional
investors, and media on Wednesday 17 July 2024 at 10.00 am - 12.30 pm (BST).
The Company also expects to announce a trading update for the six months ended
30 June 2024 on the same day.
The event will focus on the capabilities of the world's largest human
challenge trial unit and how it will enhance and broaden hVIVO's services, as
well as covering the Group's trading update. CEO Yamin 'Mo' Khan will chair
the event that will include speakers from across the Group, as well as a
fireside chat with a number of external speakers discussing the utility of
human challenge trials. There will also be an opportunity for attendees to
take part in Q&A sessions with the speakers and to tour the laboratory and
challenge trial unit.
Analysts, institutional investors and media are welcome to attend the
in-person event. Due to restrictions on numbers, it will not be possible for
all interested parties to attend in-person, however, a live webcast will be
available on the Company's website for retail investors and others to view the
presentations here
(https://stream.brrmedia.co.uk/broadcast/666c6274ee30aaf32018b8d1) .
To register your interest for the event or webcast, please contact Walbrook PR
on +44 20 7933 8780 or email hvivo@walbrookpr.com
(mailto:hvivo@walbrookpr.com) . A recording of the presentation will be made
available on the Company's website after the event.
For further information please contact:
hVIVO plc +44 (0) 20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7220 0500
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward
Peel Hunt LLP (Joint Broker) +44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Euronext Growth Adviser and Joint Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or hvivo@walbrookpr.com
Stephanie Cuthbert / Phillip Marriage / +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /
Louis Ashe-Jepson
+44 (0) 7747 515 393
Notes to Editors
About hVIVO
hVIVO plc (http://www.hvivo.com) (ticker: HVO) (formerly Open Orphan plc) is
a fast growing specialist contract research organisation (CRO) and the world
leader in testing infectious and respiratory disease vaccines and therapeutics
using human challenge clinical trials. The Group provides end-to-end early
clinical development services to its large, established and growing repeat
client base, which includes four of the top 10 largest global biopharma
companies.
The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Group has
world class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB brand, which includes virology,
immunology biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and clinical trial
site services.
hVIVO runs challenge trials in London - its new state-of-the-art facilities
in Canary Wharf opened in 2024 and is the world's largest commercial human
challenge trial unit, with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers / patients for its
studies, the Group leverages its unique clinical trial recruitment capability
via its FluCamp (http://www.flucamp.com/) volunteer screening facilities
in London and Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTQFLFBZDLLBBL